durvalumab + danvatirsen + chemotherapy

This is a combination regimen consisting of **durvalumab** (a fully human monoclonal antibody targeting programmed death-ligand 1, PD-L1), **danvatirsen** (an antisense oligonucleotide that inhibits signal transducer and activator of transcription 3, STAT3, by binding to its mRNA and preventing protein translation), and **chemotherapy** (generally platinum-based, but specific agents depend on disease context). - **Durvalumab** works by blocking PD-L1 from interacting with PD-1 and CD80, releasing the inhibition of immune responses against tumor cells. - **Danvatirsen** reduces STAT3 expression, reverses the immunosuppressive tumor microenvironment, and promotes tumor cell apoptosis. - **Chemotherapy** acts by direct cytotoxicity to tumor cells; the exact mechanism varies with the agent(s) used (e.g., DNA crosslinking by platinum compounds). This combination has been investigated in clinical trials for various advanced cancers, such as non-small cell lung cancer and head and neck squamous cell carcinoma, aiming to improve response rates through synergistic targeting of immune checkpoints and oncogenic signaling pathways[4][5][8]. Danvatirsen development was discontinued by the original sponsor, so further development of this specific combination may be limited[8].

Other names

durvalumab plus danvatirsen plus chemotherapy